Insulet Corporation Price Target Lowered by Truist to $360 but Buy Rating Reaffirmed Amid Omnipod 5 Growth | MarketWire

Truist cuts Insulet's price target to $360, maintaining Buy rating as Omnipod 5 drives strong Q4 results.